Innovacell Biotechnologie AG is an innovative company that concentrates on cell-tissue therapy for the treatment of incontinence. It currently has two personalised medical product sunder development in multi-national clinical studies, ICES13 and ICEF15. Innovacell has also successfully developed a minimally-invasive implantation method based on Sonoject®, a patented instrument which is guided by ultra-sound to re-inject a patient's own muscle cells. To date, more around 1,000 patients have been treated in clinical studies.
Pressemitteilung: 2014-01-07Norgine & Innovacell: Exclusive licensing agreement Norgine and Innovacell enter into an exclusive Licensing agreement for ICEF15 - an Innovative personalised cell therapy to treat faecal incontinence read more »